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A 63-year old man was referred to us after three rapid recurrences of low-grade urethral papillary transitional cell carcinoma of
the bulbar urethra, after repeated primary excision. Cystoscopy conﬁrmed 3-4 low-grade urethral transitional cell carcinomas,
which were subsequently fulgurated. After urethral healing, a solution of Mitomycin C (40mg/80cc) was instilled into the urethra
for ﬁfteen minutes and held in place with a penile clamp. Urethral instillations were repeated weekly for six weeks. The patient
is currently disease-free more than one year and three months posttreatment. This case highlights the successful treatment of
urethral carcinoma with topical chemotherapy, which is usually reserved for the bladder, using a slight modiﬁcation of standard
technique.
Copyright © 2008 E. J. Melonakos and R. A. Santucci. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Cancer in the male urethra is rare, representing less than
0.5% of all malignancies in males [1, 2]. It is seen primarily
in the sixth decade of life, with approximately 55–65% of
tumors located in the bulbar part of the urethra and 30–35%
occur in the anterior urethra [3]. Prognoses are not good for
patients with advanced stages of bulbar urethral cancer, with
only a 26% survival rate [4]. Bulbomembranous urethral
tumors are typically diagnosed later than more anterior
cancers, but prognosis is good if treated at early stages [4].
The chief problem in treating urethral carcinoma is how to
expose the urethra to topical chemotherapy agents such as
BCG or Mitomycin C. We present a case illustrating how
to place chemotherapy eﬀectively in the urethra, to curative
eﬀect in a patient with multiple previous failures of simple
fulgaration.
2. CASE PRESENTATION
A 63-year old male was referred to our practice with recur-
rent, low-grade, bulbar urethra transition cell carcinoma
which had recurred after two previous excisions.
The patient was taken to the operating room for a
third excision, where several urethral tumors were removed.
Pathology showed T1, Grade 1 urothelial carcinoma. A large
caliber urethral stricture in the area was also treated with
urethrotomy at the same time. After surgical excision, he
underwent 6 weekly installations of 40mg Mitomycin C
reconstituted in 80cc of saline. While the usual method
of intravesical chemotherapy involves installation through a
bladdercatheter,inthiscaseweusedacatheter-tip“Toomey”
syringe (Bard; Covington, Ga, USA) to gently instill the
medication into the urethral meatus, then used a penile
clamp (Storz; Culver City, Calif, USA) to keep the column
of medication in the urethra for 15 minutes.
The patient suﬀered usual side eﬀects of Mitomycin,
including self-limited fatigue, dysuria, daytime urinary fre-
quency up to every hour, and nocturia 2-3X nightly [5].
All symptoms but nocturia resolved by the 6th treatment.
He had cystoscopy and voided cytology examinations at 2,
6, and 12 and 18 months without recurrence of stricture
or development of urethral cancer recurrences. (Previous
recurrences X3 had been evident within 3 months of
resection). The urethra appeared largely pink and healthy,
with only small areas of white scar tissue marking the areas
of previous urethral tumor resection.2 Advances in Urology
3. DISCUSSION
IntraurethralMitomycinCispossible
We report the successful application of Mitomycin C to
urethral carcinoma, by a method of intraurethral installation
and penile clamping to keep the agent in urethral contact.
L o c a ls i d ee ﬀects included irritative voiding symptoms, but
seemingly no more severe than after intravesical administra-
tion. Other authors have described signiﬁcant complications
including urethral stricture after Mitomycin was mixed into
lidocaine jelly and placed into the urethra in one case. Penile
and urethral complications of Mitomycin have also been
reported after intravesical administration: (1) glans necrosis
after high dose (60mg) [6], (2) urethral sloughing, and
(3) necrosis of the corpus spongiosum [7]. Despite these
rare complications, practitioners wishing to treat urethral
superﬁcial transitional cell carcinoma with topical agents
might consider this simple approach in their patients.
4. CONCLUSION
To our knowledge, this is the ﬁrst case of bulbar, low-grade
papillary transitional cell carcinoma treated successfully by
applicationofliquidMitomycinC.Thistechniqueprovidesa
method for application of Mitomycin directly to the urethral
mucosa.
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